Grace Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Grace Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,077	Closed	-$146K	–	203
2021 Q1	$146K	Hold	1,077	–	–	0.09%	167
2020 Q4	$152K	Sell	1,077 -181	-14%	-$23.2K	0.1%	169
2020 Q3	$140K	Sell	1,258 -5	-0.4%	-$561	0.11%	149
2020 Q2	$141K	Buy	+1,263	New	+$124K	0.12%	139
2019 Q3	–	Sell	-18,374	Closed	-$1.61M	–	184
2019 Q2	$1.61M	Sell	18,374 -1,950	-10%	-$166K	0.77%	39
2019 Q1	$1.84M	Buy	+20,324	New	+$1.73M	0.72%	43

Other funds holding XBI

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Grace Capital's XBI Position: Q2 2021 in Review

Grace Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2021, closing a stake of 1,077 shares — an estimated $146K sold.

Grace Capital first reported a position in XBI in Q1 2019 and held it in 6 quarters. The position peaked at $1.84M in Q1 2019. 663 funds tracked by Wall St. Rank hold XBI as of Q2 2021.

Grace Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2021 after selling out during the quarter.
Grace Capital sold 1,077 State Street SPDR S&P Biotech ETF shares in Q2 2021, an estimated $146K.
Grace Capital first reported a position in State Street SPDR S&P Biotech ETF in Q1 2019 and held it in 6 quarters.
Grace Capital's State Street SPDR S&P Biotech ETF position peaked at $1.84M in Q1 2019.
663 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2021.

Based on Grace Capital's 13F filing for Q2 2021, filed 11 Aug 2021.